



## **Arcuro Medical Receives FDA Regulatory Clearance**

**Misgav, Israel, 19 June 2018** – [Arcuro Medical Ltd. \("Arcuro"\)](#), a portfolio company of [The Trendlines Group Ltd. \("The Trendlines Group" or "Trendlines"\)](#) (SGX: 42T; OTCQX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBall™ meniscus repair system.

Meniscus tears are a common occurrence in many population groups: professional athletes, people who engage in daily sport activities, the ageing population, and people predisposed to cartilage problems.

To maintain knee functionality, current practice seeks to avoid removal of the meniscus, and prefers arthroscopic repair techniques. Shortcomings of current repair devices, however, include rigid implants, difficult-to-use delivery systems, and leave a knot in the joint space. These can cause poor repair quality, increased intraoperative failure, long-term damage to the meniscus, and device failures.

Arcuro has developed an all-suture meniscus repair system that preserves knee functionality and is secure, reliable, and effective. Arcuro completed an extensive and very successful series of pre-clinical studies in the United States and Israel. Arcuro believes that with its easy-to-use system, an all-suture implant, with no knot in the joint space, more surgeons will confidently choose to repair the meniscus instead of removing it. As a result, Arcuro expects to convert a significant portion of the meniscus removal procedures performed annually to repair procedures. According to MedDevice Tracker, the global meniscus repair market is currently valued at over US\$300 million<sup>1</sup>.

Arcuro submitted a patent at national phase in China, Israel, the United States, and Europe. The patent in the United States was recently granted.

"We are very excited to have achieved FDA clearance in addition to the news of receiving our US patent. These two important milestones will enable the company to begin its clinical evaluation phase straight away," remarked Lee Ranon, CEO of Arcuro.

Chairman and CEO of The Trendlines Group, Steve Rhodes added: "We are very proud of the progress that the Arcuro team has made towards bringing their SuperBall™ meniscus repair system to market. We look forward to following their progress in improving patient outcomes and reducing surgeries in a market seeking a solution to this common and painful problem."

### **About The Trendlines Group Ltd.**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve

---

<sup>1</sup> MedDevice Tracker, March 2017, Arthroscopy and Sports Medicine Devices Market.

the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

\*\*\*\*\*

#### **Investor Contact Information**

##### **Israel:**

Shira Zimmerman, The Trendlines Group

[shira@trendlines.com](mailto:shira@trendlines.com)

Tel: +972.72.260.7000

##### **Singapore and China:**

Reyna MEI, Financial PR

[reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)

Tel: +65.6438.2990

---

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).